A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 (Solbinsiran) in Adults With Severe Hypertriglyceridemia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 (Solbinsiran) in Adults With Severe Hypertriglyceridemia
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
Inclusion Criteria:
Exclusion Criteria:
LillyTrials@Lilly.com317-615-4559
clinical_inquiry_hub@lilly.com
Phoenix, Arizona 85014, United States
602-730-9500
Tucson, Arizona 85741, United States
Northridge, California 91325, United States
Winter Park, Florida 32789, United States
Covington, Kentucky 41011, United States
Worcester, Massachusetts 01655, United States
San Antonio, Texas 78215, United States
Newport News, Virginia 23606, United States
Luoyang Shi, 471003, China
13653880139
Chūōku, 103-0002, Japan
Kamakura-shi, 247-0056, Japan
Suita-shi, 565-0853, Japan
520-333-4515
310-289-9955
562-997-1000
909-590-8409
818-678-4900
904-541-8225
305-631-0619
786-502-4303
407-740-8078
773-275-3500
317-852-8280
410-824-1341
702-233-4700 ext 2
215-676-6696
646-962-5558
212-241-9101
949-491-0710
214-693-0904
210-253-3426
518-428-6859
757-232-8836
425-869-6828
418-545-1252
8193731128
13810103532